Australian Clinical Labs (ASX:ACL) Other Current Receivables: A$-14.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ACL Australian Clinical Labs Ltd ASX:ACL
56 GF Score
Price A$2.38
GF Value A$3.06
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Australian Clinical Labs Other Current Receivables?

Australian Clinical Labs ASX:ACL -0.83% 56 Other Current Receivables is A$-14.0 Mil as of Dec. 2025. GuruFocus rates ASX:ACL with a GF Score™ of 56/100 and a GF Value™ of A$3.06 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Australian Clinical Labs's Other Current Receivables for the quarter that ended in Dec. 2025 was A$-14.0 Mil.

Australian Clinical Labs's quarterly Other Current Receivables increased from Dec. 2024 (A$-11.92 Mil) to Jun. 2025 (A$13.52 Mil) but then stayed the same from Jun. 2025 (A$13.52 Mil) to Dec. 2025 (A$-14.02 Mil).

Australian Clinical Labs's annual Other Current Receivables declined from Jun. 2023 (A$22.36 Mil) to Jun. 2024 (A$18.18 Mil) and declined from Jun. 2024 (A$18.18 Mil) to Jun. 2025 (A$13.52 Mil).

Australian Clinical Labs Other Current Receivables Related Terms

Australian Clinical Labs Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Australian Clinical Labs's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Australian Clinical Labs Other Current Receivables Chart

Australian Clinical Labs Annual Data
Trend Dec20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Receivables
Get a 7-Day Free Trial 18.86 26.23 22.36 18.18 13.52

Australian Clinical Labs Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 18.18 -11.92 13.52 -14.02
ASX:ACL
56GF Score
Australian Clinical Labs Ltd ASX:ACL
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Australian Clinical Labs Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of A$-14.0 Mil mean?
Australian Clinical Labs (ASX:ACL) has a Other Current Receivables of A$-14.0 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Australian Clinical Labs and its competitors.
Is Australian Clinical Labs' Other Current Receivables too high?
Australian Clinical Labs' current Other Current Receivables is A$-14.0 Mil. Overall, Australian Clinical Labs has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' Other Current Receivables compare to TMO and DHR?
Australian Clinical Labs' Other Current Receivables of A$-14.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Diagnostics & Research company?
A good Other Current Receivables depends on the Medical Diagnostics & Research industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Australian Clinical Labs and its competitors. Australian Clinical Labs's current Other Current Receivables is A$-14.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Modestly Undervalued. The stock's GF Value™ is A$3.06, compared to a current price of A$2.38 — trading 22.2% below its estimated fair value. The current Other Current Receivables is A$-14.0 Mil. Australian Clinical Labs' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current Other Current Receivables is A$-14.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?

Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued. The current stock price of A$2.38 is trading 22.2% below its estimated GF Value™ of A$3.06. GuruFocus considers Australian Clinical Labs to be Modestly Undervalued.

Key valuation signals for ASX:ACL:

  • Other Current Receivables: A$-14.0 Mil
  • GF Value™: A$3.06 vs. price of A$2.38 (22.2% below fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Australian Clinical Labs Business Description

Address 1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
56GF Score

Get the complete analysis for ASX:ACL

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.38
Price
A$3.06
GF Value